Love the excitement from this wonderful team. Congratulations to all at @imagobiorx

This morning, we announced our recent $33M expanded financing, exciting advancements in our diabetes and obesity clinical program and revealed our new name change to #StructureTx! Learn more about our latest milestones and what's to come here: bit.ly/3SiMmXY

We are proud to be chosen as one of this year’s #Fierce15 winners! Thank you, FierceBiotech, for recognizing the work of our amazing team and our mission to develop the next generation of #cytokine therapeutics. Learn more: bwnews.pr/3DzhGx5 #Fierce152022

A fantastic year of growth for this team, and I'm glad to see it recognized with a spot on the #Endpoints11

It has been a year of significant growth for Surrozen Inc. and its #Wnt focused pipeline, including a new deal announced today with Boehringer Ingelheim for its lead program in retinal disease

Even though often called 'benign tremor,' the effects of essential tremor have significant impact on patients.

We're excited to announce the acquisition of Redpin Therapeutics and its leading chemogenetics platform. This acquisition marks our expansion into neurology, with a pipeline to address severe diseases such as #epilepsy and #trigeminalneuralgia. Learn more: kriyatherapeutics.com/2022/11/16/kri…

Congratulations to client Imago on today's news! Proud to have worked with this incredible team over the past few years as they grew as a company and advanced bomedemstat.

My #Spotifywrapped was led by two songs from James Gunn playlists that my 5 year old requests daily on the drive to school: “the silly dance song” (Do You Wanna Taste It) from Wig Wam and “the baby Groot song” (Mr Blue Sky) from Jeff Lynne's ELO

We’re thrilled to announce our $100 million Series C financing, which will be used to advance our pipeline of differentiated cytokine therapeutics. Learn more about the #financing & upcoming #JPM23 presentation: bit.ly/3CwNX6n

Tomorrow, our CEO, Debanjan Ray, will present at the 41st Annual J.P. Morgan Healthcare Conference at 1:30 p.m. PT to discuss Synthekine’s rapid growth, recent Series C financing, and evolving therapeutic pipeline. Learn more: bit.ly/3CwNX6n #JPM2023

We're collaborating with Regeneron to discover, develop and commercialize potentially transformative #Treg therapies for people with #ulcerativecolitis, #crohns and other #autoimmune and #inflammatorydiseases. Learn more: bit.ly/40laZao. #IBD

Today we announced positive results from our Ph3 EXPLORER-CN trial of mavacamten for the treatment of Chinese patients w/ oHCM. Learn more about the data and the impact access will have for patients in need: bit.ly/41GMxRj #LIAN $LIAN #data

Hi everyone - I am looking for my next career opportunity. I have 20+ years of experience, including a journalism career (Bloomberg, bylines in NYT, SF Chron) + a decade in PR, working at an agency (W2O) and in-house at biopharma (J&J, Audentes, Resilience & Kriya). DMs are open!

The transition of all the usual suspect biotech companies from covid plays to weight loss plays will be entertaining to watch.

Next month, Truvian will present performance of its blood testing solution from a recent multisite #clinicalstudy at the ❃ Annual Scientific Meeting. Read more about our poster presentation: bit.ly/3PzqXes

Winners | Losers of Biopharma for 2023 A newsroom-wide list with dozens of entries ... and emojis to match Check out our review of the year: endpts.com/biotech-and-ph…

The Breakthrough of the Year @AAAS Bhaumik Prize goes to the 2 scientists who pushed/fought to get GLP-1 drugs to treat obesity (which took decades!) aaas.org/news/innovator… by Meagan Phelan, with the whole, fascinating story pleased to be a member of the selection committee

Synthekine Joins Quest To Tame IL-2 In Cancer Therapies. First clinical data from Synthekine’s IL-2 candidate and that of rivals Medicenna were presented at the AACR, suggesting there’s life in the modality yet.      Related StoriesNovartis... ow.ly/Uguv105pFPy #PharmaScrip